# Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease

> **NCT07659353** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 320 (estimated)

## Conditions studied

- Chrohn's Disease

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Azathioprine (AZA)

## Key facts

- **NCT ID:** NCT07659353
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07659353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07659353, "Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07659353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*